Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
November 2018
-
Media ReleaseFDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indicationPromacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation Approval…
-
Media ReleaseNovartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancerKisqali is the CDK4/6 inhibitor with the largest body of first-line evidence demonstrating consistent, superior and sustained efficacy vs. endocrine therapy alone[1] CHMP opinion is…
-
Key ReleaseAlcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and LondonBasel, November 13, 2018 - Novartis today announced that Alcon has filed an initial Form 20-F registration statement with the US Securities and Exchange Commission (SEC) in relation to the previously…
-
Media ReleaseNew Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patientsEntresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker…
-
Media ReleaseNovartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms26 potential blockbusters in confirmatory development[1]. 13 projects in clinical development across Cell, Gene & Radioligand therapies. 60 major submissions[2] planned from 2019 to 2021…
-
Media ReleaseSandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needsDecision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is…
-
Media ReleaseNovartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncologyAdditional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2-…
October 2018
-
Media ReleaseSandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz)Biosimilar HyrimozTM (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity **Biosimilars are critical to sustaining US healthcare system, providing…
-
Media ReleaseNovartis announces clinical collaboration with Pfizer to advance the treatment of NASHAgreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has…
-
Media ReleaseTwo-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMDYear two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in…
-
Media ReleaseNovartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritisNew Cosentyx® (secukinumab) label to include dosing flexibility up to 300 mg, based on clinical response, and 24-week structural data with subcutaneous (sc) regimens[1] Cosentyx inhibits…
-
Media ReleaseAlcon to develop SMART Suite digital health platform for cataract surgerySMART Suite by Alcon will drive innovation in ophthalmology delivering personalized and seamless end-to-end care for cataract patients As an open, secure cloud-enabled ecosystem, SMART…
Pagination
- ‹ Previous page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- …
- 100
- › Next page